Screener
Rapport Therapeutics, Inc. RAPP Income Statement
| Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | ||
|---|---|---|---|---|---|---|
| $0— | $0— | $20M— | —— | —— | ||
| $34.32M+54.0% | $51.41M+127% | $32.72M+67.2% | $30.26M+75.9% | $22.28M+43.3% | ||
| $9.77M— | $9.39M+37.8% | $11.5M+52.6% | —— | —— | ||
| $44.09M+47.0% | $60.81M+106% | $44.22M+63.1% | $38.51M+63.7% | $29.99M+38.6% | ||
| -$44.09M-47.0% | -$60.81M-106% | -$24.22M+10.7% | -$38.51M-63.7% | -$29.99M-38.6% | ||
| $3.85M+25.8% | $4.19M+51.6% | $4.36M+43.1% | $4.75M+34.0% | $3.06M-25.4% | ||
| -$40.24M-49.4% | -$56.62M-112% | -$19.86M+17.5% | -$33.76M-69.0% | -$26.93M-53.5% | ||
| -$0.84-18.3% | -$1.19-58.7% | -$0.42+38.2% | -$0.71-492% | -$0.71-42.0% | ||
| -$43.89M-47.6% | -$60.59M-107% | -$23.99M+10.7% | -$38.24M-64.4% | -$29.73M-38.8% | ||
| -$44.09M-47.0% | -$60.81M-106% | -$24.22M+10.7% | -$38.51M-63.7% | -$29.99M-38.6% |
FAQ
- Is Rapport Therapeutics, Inc. profitable?
- Rapport Therapeutics, Inc. is not currently profitable: it reported a net loss of $150.5M over the trailing twelve months.
- What is Rapport Therapeutics, Inc.'s earnings per share?
- Rapport Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-3.16.
- Where does Rapport Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Rapport Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.